{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:52:52Z","timestamp":1784775172354,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12881-017-0403-x","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T15:56:55Z","timestamp":1494863815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy"],"prefix":"10.1186","volume":"18","author":[{"given":"Yoo-Mi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Bum","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Kun","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"403_CR1","first-page":"299","volume":"4","author":"TM Cox","year":"2010","unstructured":"Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics. 2010;4:299\u2013313.","journal-title":"Biologics"},{"key":"403_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12804","volume":"165","author":"AS Thomas","year":"2014","unstructured":"Thomas AS, Mehta A, Hughes DA. Gaucher disease: haematological presentations and complications. Br J Haematol. 2014;165:427\u201340.","journal-title":"Br J Haematol"},{"key":"403_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","volume":"4","author":"A Nagral","year":"2014","unstructured":"Nagral A. Gaucher disease. J Clin Exp Hepatol. 2014;4:37\u201350.","journal-title":"J Clin Exp Hepatol"},{"key":"403_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14712590802573395","volume":"9","author":"J Charrow","year":"2009","unstructured":"Charrow J. Enzyme replacement therapy for Gaucher disease. Expert Opin Biol Ther. 2009;9:121\u201331.","journal-title":"Expert Opin Biol Ther"},{"key":"403_CR5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s10545-014-9680-0","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Hughes DA, Waldek S, et al. Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37:953\u201360.","journal-title":"J Inherit Metab Dis"},{"key":"403_CR6","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/ajh.24056","volume":"90","author":"J Charrow","year":"2015","unstructured":"Charrow J, Scott CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015;90:S19\u201324.","journal-title":"Am J Hematol"},{"key":"403_CR7","first-page":"407","volume":"3","author":"D Elstein","year":"2009","unstructured":"Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics. 2009;3:407\u201317.","journal-title":"Biologics"},{"key":"403_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1872214808666140115111350","volume":"8","author":"S Ortolano","year":"2014","unstructured":"Ortolano S, Vi\u00e9itez I, Navarro C, Spuch C. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:9\u201325.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"403_CR9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.gene.2012.06.090","volume":"507","author":"HW Park","year":"2012","unstructured":"Park HW, Lee Y, Kim GH, Lee BS, Kim KS, Yoo HW, et al. Novel frameshift mutation (Pro171fsX21) in neonatal type 2 Gaucher\u2019s disease. Gene. 2012;507:170\u20133.","journal-title":"Gene"},{"key":"403_CR10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ymgme.2011.12.010","volume":"105","author":"BH Lee","year":"2012","unstructured":"Lee BH, Kim DY, Kim GH, Cho KJ, Yoon HK, Yoo HW. Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease. Mol Genet Metab. 2012;105:522\u20134.","journal-title":"Mol Genet Metab"},{"key":"403_CR11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/mrd.1080350415","volume":"35","author":"P Nissley","year":"1993","unstructured":"Nissley P, Kiess W, Sklar M. Developmental expression of the IGF-II\/mannose 6-phosphate receptor. Mol Reprod Dev. 1993;35:408\u201313.","journal-title":"Mol Reprod Dev"},{"key":"403_CR12","doi-asserted-by":"crossref","first-page":"F163","DOI":"10.1136\/fn.82.2.F163","volume":"82","author":"DL Stone","year":"2000","unstructured":"Stone DL, Carey WF, Christodoulou J, Sillence D, Nelson P, Callahan M, et al. Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed. 2000;82:F163\u20136.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"403_CR13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2006-924556","volume":"37","author":"B Hoffmann","year":"2006","unstructured":"Hoffmann B, Schwahn B, Knobbe CB, Vogel M, Blohm M, Mayatepek E, et al. Acute neuronopathic Gaucher disease complicated by fatal gastrointestinal bleeding. Neuropediatrics. 2006;37:163\u20135.","journal-title":"Neuropediatrics"},{"key":"403_CR14","first-page":"346","volume":"86","author":"JM Henderson","year":"1991","unstructured":"Henderson JM, Gilinsky NH, Lee EY, Greenwood MF. Gaucher\u2019s disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells. Am J Hematol. 1991;86:346\u20138.","journal-title":"Am J Hematol"},{"key":"403_CR15","first-page":"425","volume":"40","author":"I Yamadori","year":"1990","unstructured":"Yamadori I, Morikawa T, Kobayashi S, Ohmori M. Gaucher\u2019s disease type I. Report of a case with prominent deposition of ceroid in splenic endothelial cells and intestinal smooth muscle fibers. Acta Pathol Jpn. 1990;40:425\u201330.","journal-title":"Acta Pathol Jpn"},{"key":"403_CR16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.20504","volume":"80","author":"NJ Weinreb","year":"2005","unstructured":"Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005;80:223\u20139.","journal-title":"Am J Hematol"},{"key":"403_CR17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35:613\u201320.","journal-title":"Drugs Future"},{"key":"403_CR18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313:695\u2013706.","journal-title":"JAMA"},{"key":"403_CR19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758409","author":"TM Cox","year":"2016","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2016. doi:\n10.1182\/blood-2016-12-758409\n\n.","journal-title":"Blood"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-017-0403-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T15:56:59Z","timestamp":1494863819000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/s12881-017-0403-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1186\/s12881-017-0403-x","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]},"article-number":"55"}}